Join our quest to form the largest human representation of a bird - symbolising freedom from taboos. Unite with us on September 29, 2024, in Hyderabad to raise awareness and support the fight against breast cancer. Register now to make a difference!
Every 4 minutes – a woman is diagnosed with breast cancer.
Every 8 minutes – a woman succumbs to breast cancer.
For every 2 women diagnosed with breast cancer – one succumbs from it.
In the global breast cancer incidence and rates in 2022 for women India ranks Third.
In the global breast cancer deaths in 2022 for women India ranks First.
Breast Cancer is a formidable adversary, one that affects millions of women worldwide. Yet, it is through collective effort, awareness and support that we can confront this challenge head-on and make a significant difference.
Unite with us on September 29, 2024, in Hyderabad to raise awareness and support the fight against breast cancer. Register now to make a difference!
The Sudha Reddy Foundation is dedicated to health, child education, and women’s empowerment. Our foundation has a history of collaboration with The Breast Cancer Research Foundation, funding innovative research aimed at preventing and curing breast cancer. Together, we strive to improve diagnosis, treatment, and outcomes globally. The Sudha Reddy Foundation is committed to the goal of zero deaths from breast cancer. Through the Pink Power Run marathon, our mission is to raise awareness about breast cancer while fostering a community of strength and solidarity among survivors, their families, and supporters. We aim to educate the public, promote early detection, and encourage a healthier, more informed society.
MEIL proudly partners in national pride with a steadfast commitment to timely project delivery and a strong focus on social and environmental impact. Through the MEIL Foundation, we strive to achieve our Corporate Social Responsibility (CSR) goals by supporting vital healthcare initiatives. Notable projects include the Special Diet Program for children at MNJ Hospital and the development of the new Oncology Department at NIMS.
